Global Systemic Lupus Erythematosus Market by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Industry Insights

In 2017, the global market for systemic lupus, erythematosus was valued at USD 1.87 million. The market is expected to grow at 7.0% during the forecast period. Market growth is expected to accelerate with the arrival of key pipeline agents that promise greater efficacy than existing therapies.

The treatment of autoimmune conditions is much more effective with biologics and doctors are increasingly trusting them. The FDA and EMA approved Benlysta in 2011, the first biologic approved in the last 50 years. In 2011, the FDA and EMA approved Benlysta. Market adoption of Benlysta is hindered by its low to moderate efficacy in treating patients with severe systemic Lupus Erythematosus (SLE), and Lupus Nephritis. GSK is conducting clinical trials to assess the efficacy of Benlysta combined with rituximab in order to increase market adoption.

Some of the pipeline biologics currently undergoing phase III clinical trials will be available for sale in 2018-2021. The European League against Rheumatism, which sets guidelines for reimbursement for therapies, defines the eligibility for biologics on the market.

These guidelines state that physicians must only prescribe biologics to patients if two or more non-biologic immunesuppressants fail to improve the disease activity. These guidelines have been used by many countries to determine their reimbursement policies. They vary greatly. The higher demand for Benlysta is due to the availability of healthcare services and better coverage. In contrast, in developing countries, access to biologics is limited by high costs and a lack of government-funded coverage.

Drug Class Insights

In 2017, the largest revenue share was held by immunosuppressants, which was valued at USD 1.01 million. Methotrexate is widely used worldwide, and this has contributed to the growth of the market. Biologics was placed after the segment due to Benlysta's slow penetration.

Biologics will see the highest CAGR at 12.0% over the forecast period. The market will grow if new biologics are introduced with better efficacy. Benlysta, the first approved on-label SLE biologic, has been a success with mild to moderate SLE. For severe forms of SLE, however, safety and efficacy are still being evaluated. Other biologic agents, such as rituximab, can be used off-label to treat systemic lupus. They are not as dangerous as immunosuppressants and corticosteroids.

Route of Administration Insights

In 2017, the oral segment accounted for more than half the total value of the SLE market. In 2017, the segment was closely followed by intravenous (which accounted for just 35.0%). Small molecule drugs are easy to administer and continue to be the main treatment for SLE.

The forecast period sees the subcutaneous segment growing at a 10.4% CAGR. One of the main growth stimulants in the subcutaneous segment is the recent approval of Benlysta and Rituximab subcutaneous formulations in many countries, including the U.S.A and several European countries. These formulations allow patients to self-administrate these therapies which increases prospects for this segment.

Regional Insights

The market was dominated by North America in 2017, with the U.S. leading the charge. It is expected to maintain its leadership position until 2025 with a CAGR 8.1% over the forecast period. The region's market is growing due to a higher prevalence of SLE and better coverage for specialty drugs, as well as a better healthcare infrastructure.

Europe was the second largest regional market in 2017, with a value of USD 397.6 millions. It can be attributed that Benlysta was approved by five European Union countries: the U.K. Germany Spain Italy France and Spain. Due to its availability in both forms, belimumab is more commonly used because of better coverage policies.

LATAM, APAC, and MEA are the least prominent in the market. These regions have low revenue generation due to a variety of factors. The lowest rheumatologist-to-population ratio can also be blamed for preventing early diagnosis and treatment. Patients are not able to access belimumab, even though it is available in these areas. Patients in low-income countries often seek out the public health system, which is not equipped to provide quality medical care.

SLE Market Share Information

GlaxoSmithKline is the market leader, followed by Roche, Pfizer and Novartis. Bayer and Sanofi are also prominent players. GlaxoSmithKline is conducting clinical trials for Benlysta as well as rituximab in collaboration with Roche to evaluate their combined effectiveness in treating severe SLE symptoms. Novartis also developed a biosimilar of rituximab that is affordable and can be used to promote the use of biologic therapies in developing countries.

Manufacturers focus their strategic efforts on developing biologics that are more effective. Aurinia Pharmaceuticals and Astra Zeneca will be launching promising therapies in the near future, including Lupuzor and Voclosporin.

The Report Covers Certain Segments

This report predicts revenue growth at the global, regional and country levels. It also provides analysis of industry trends in each sub-segment from 2014 to 2025. Up Market Research has divided the global systemic Lupus Erythematosus market report by drug classes, route and region.

• The Outlook for Drug Classes (Revenue, USD million, 2014-2025)

  • NSAIDs

  • Corticosteroids

  • Antimalarials

  • Immunosuppressants

  • Biologics

• Route of Administration Outlook (Revenue USD Million, 2014 - 2025).

  • Oral

  • Intravenous

  • Subcutaneous

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Greece

    • Sweden

    • Norway

    • Poland

    • E

  • Asia Pacific

    • Japan

    • China

    • Hong Kong

    • Taiwan

    • South Korea

    • New Zealand

    • Australia

    • India

    • Malaysia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • Turkey

    • Saudi Arabia

    • Kuwait

    • Israel

    • South Africa

Up Market Research published a new report titled “Systemic Lupus Erythematosus Market research report which is segmented by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids), By Players/Companies GlaxoSmithKline in collaboration with Roche is conducting clinical trials with Benlysta and rituximab to determine their combined efficacy in treating severe symptoms of SLE Furthermore, Novartis developed a biosimilar rituximab at a low cost, Roche, Pfizer, GlaxoSmithKline, Sanofi Among key strategies, which is used as an off label drug to fuel the adoption of biological therapies in developing regions, Novartis, Bayer”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Systemic Lupus Erythematosus Market Report Segments:

The market is segmented by Drug Class (NSAIDs, Biologics, Immunosuppressants, Antimalarials, Corticosteroids).

Systemic Lupus Erythematosus Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Systemic Lupus Erythematosus Market

Overview of the regional outlook of the Systemic Lupus Erythematosus Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Systemic Lupus Erythematosus Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Systemic Lupus Erythematosus Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. NSAIDs

                2. Biologics

                3. Immunosuppressants

                4. Antimalarials

                5. Corticosteroids

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Systemic Lupus Erythematosus Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Systemic Lupus Erythematosus Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.